Indications
Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Composition
- Active substance
- mogamulizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Poteligeo
- Active substance
- mogamulizumab
- ATC code
- L01XC25
- Therapeutic area
- Sezary Syndrome, Mycosis Fungoides
- Marketing authorisation holder
- Kyowa Kirin Holdings B.V.
- Status
- Authorised